These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 30453199)

  • 1. Effect of glatiramer acetate on cerebral grey matter pathology in patients with relapsing-remitting multiple sclerosis.
    Crescenzo F; Marastoni D; Zuco C; Pitteri M; Magliozzi R; Monaco S; Calabrese M
    Mult Scler Relat Disord; 2019 Jan; 27():305-311. PubMed ID: 30453199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of switching from glatiramer acetate 20 mg/daily to glatiramer acetate 40 mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study.
    Zivadinov R; Bergsland N; Hagemeier J; Tavazzi E; Ramasamy DP; Durfee J; Cherneva M; Carl E; Carl J; Kolb C; Hojnacki D; Weinstock-Guttman B
    J Neurol Sci; 2018 Apr; 387():152-156. PubMed ID: 29571854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the effect of glatiramer acetate on cerebral gray matter atrophy in multiple sclerosis.
    AbdelRazek MA; Tummala S; Khalid F; Tauhid S; Jalkh Y; Khalil S; Hurwitz S; Zurawski J; Bakshi R
    J Neurol Sci; 2023 Jan; 444():120501. PubMed ID: 36481574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of fingolimod on focal and diffuse grey matter damage in active MS patients.
    Bajrami A; Pitteri M; Castellaro M; Pizzini F; Romualdi C; Montemezzi S; Monaco S; Calabrese M
    J Neurol; 2018 Sep; 265(9):2154-2161. PubMed ID: 29938336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cortical and Subcortical Morphometric and Iron Changes in Relapsing-Remitting Multiple Sclerosis and Their Association with White Matter T2 Lesion Load : A 3-Tesla Magnetic Resonance Imaging Study.
    Al-Radaideh A; Athamneh I; Alabadi H; Hbahbih M
    Clin Neuroradiol; 2019 Mar; 29(1):51-64. PubMed ID: 29299614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocrelizumab reduces cortical and deep grey matter loss compared to the S1P-receptor modulator in multiple sclerosis.
    Bajrami A; Tamanti A; Peloso A; Ziccardi S; Guandalini M; Calderone M; Castellaro M; Pizzini FB; Montemezzi S; Marastoni D; Calabrese M
    J Neurol; 2024 May; 271(5):2149-2158. PubMed ID: 38289534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of immunomodulatory medication on regional gray matter loss in relapsing-remitting multiple sclerosis--a longitudinal MRI study.
    Bendfeldt K; Egger H; Nichols TE; Loetscher P; Denier N; Kuster P; Traud S; Mueller-Lenke N; Naegelin Y; Gass A; Kappos L; Radue EW; Borgwardt SJ
    Brain Res; 2010 Apr; 1325():174-82. PubMed ID: 20167205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low degree of cortical pathology is associated with benign course of multiple sclerosis.
    Calabrese M; Favaretto A; Poretto V; Romualdi C; Rinaldi F; Mattisi I; Morra A; Perini P; Gallo P
    Mult Scler; 2013 Jun; 19(7):904-11. PubMed ID: 23069877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cortical pathology in multiple sclerosis patients with epilepsy: a 3 year longitudinal study.
    Calabrese M; Grossi P; Favaretto A; Romualdi C; Atzori M; Rinaldi F; Perini P; Saladini M; Gallo P
    J Neurol Neurosurg Psychiatry; 2012 Jan; 83(1):49-54. PubMed ID: 21890577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.
    Yousuf F; Dupuy SL; Tauhid S; Chu R; Kim G; Tummala S; Khalid F; Weiner HL; Chitnis T; Healy BC; Bakshi R
    J Neurol Sci; 2017 Dec; 383():221-229. PubMed ID: 29146095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focal cortical thinning in patients with stable relapsing-remitting multiple sclerosis: cross-sectional-based novel estimation of gray matter kinetics.
    Orbach L; Menascu S; Hoffmann C; Miron S; Achiron A
    Neuroradiology; 2018 Feb; 60(2):179-187. PubMed ID: 29285552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two years' effect of dimethyl fumarate on focal and diffuse gray matter pathology in multiple sclerosis.
    Marastoni D; Crescenzo F; Pisani AI; Zuco C; Schiavi G; Benedetti G; Ricciardi GK; Montemezzi S; Pizzini FB; Tamanti A; Calabrese M
    Mult Scler; 2022 Nov; 28(13):2090-2098. PubMed ID: 35765211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disability-Specific Atlases of Gray Matter Loss in Relapsing-Remitting Multiple Sclerosis.
    MacKenzie-Graham A; Kurth F; Itoh Y; Wang HJ; Montag MJ; Elashoff R; Voskuhl RR
    JAMA Neurol; 2016 Aug; 73(8):944-53. PubMed ID: 27294295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of Glatiramer Acetate on Spinal Cord Volume in Relapsing-Remitting Multiple Sclerosis.
    Singhal T; Tauhid S; Hurwitz S; Neema M; Bakshi R
    J Neuroimaging; 2017 Jan; 27(1):33-36. PubMed ID: 27466943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis.
    Calabrese M; Rocca MA; Atzori M; Mattisi I; Favaretto A; Perini P; Gallo P; Filippi M
    Ann Neurol; 2010 Mar; 67(3):376-83. PubMed ID: 20373349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
    Comi G; Filippi M; Wolinsky JS
    Ann Neurol; 2001 Mar; 49(3):290-7. PubMed ID: 11261502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-year regional grey and white matter volume changes with natalizumab and fingolimod.
    Preziosa P; Rocca MA; Pagani E; Storelli L; Rodegher M; Moiola L; Filippi M
    J Neurol Neurosurg Psychiatry; 2020 May; 91(5):493-502. PubMed ID: 32111638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regional gray matter atrophy in relapsing remitting multiple sclerosis: baseline analysis of multi-center data.
    Datta S; Staewen TD; Cofield SS; Cutter GR; Lublin FD; Wolinsky JS; Narayana PA; ;
    Mult Scler Relat Disord; 2015 Mar; 4(2):124-36. PubMed ID: 25787188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A longitudinal study of cortical grey matter lesion subtypes in relapse-onset multiple sclerosis.
    Sethi V; Yousry T; Muhlert N; Tozer DJ; Altmann D; Ron M; Wheeler-Kingshott C; Miller DH; Chard DT
    J Neurol Neurosurg Psychiatry; 2016 Jul; 87(7):750-3. PubMed ID: 26272028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teriflunomide's effect on humoral response to Epstein-Barr virus and development of cortical gray matter pathology in multiple sclerosis.
    Zivadinov R; Ramanathan M; Hagemeier J; Bergsland N; Ramasamy DP; Durfee J; Kolb C; Weinstock-Guttman B
    Mult Scler Relat Disord; 2019 Nov; 36():101388. PubMed ID: 31525628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.